SCHEMBL57100

SCHEMBL57100

O=C(O)Oc1ccccc1Br

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.44
MAPT P10636 4/20 0.44
RAB9A P51151 3/20 0.44
NPC1 O15118 1/20 0.44
USP2 O75604 1/20 0.44
ALDH1A1 P00352 3/20 0.43
GRM4 Q14833 3/20 0.43
KDM4E B2RXH2 4/20 0.42
MEN1 O00255 2/20 0.42
POLB P06746 1/20 0.40
HPGD P15428 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HSD17B10 Q99714 2/20 0.39
ESR1 P03372 1/20 0.39
ITGB3 P05106 1/20 0.39
ITGA2B P08514 1/20 0.39
HMGB1 P09429 1/20 0.39
TSHR P16473 1/20 0.39
GGT1 P19440 1/20 0.39
PTGS1 P23219 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL57099 0.84 GRM4 (0.44) KMT2AMAPTRAB9ANPC1USP2
SCHEMBL29549932 0.84 GRM4 (0.44) KMT2AMAPTRAB9ANPC1USP2
SCHEMBL1638844 0.84 ALDH1A1 (0.43) KMT2AMAPTRAB9ANPC1USP2
SCHEMBL143632 0.83 KDM4E (0.46) KMT2AMAPTUSP2ALDH1A1KDM4E
SCHEMBL31389161 0.83 KMT2A (0.38) KMT2AMAPTRAB9ANPC1USP2
SCHEMBL11411081 0.83 KMT2A (0.38) KMT2AMAPTRAB9ANPC1USP2
SCHEMBL6959141 0.82 GRM4 (0.43) KMT2AMAPTRAB9ANPC1USP2
SCHEMBL14248985 0.81 KMT2A (0.63) KMT2AMAPTUSP2MEN1POLB
SCHEMBL1638841 0.81 FABP4 (0.46) KMT2AMAPTRAB9ANPC1USP2
SCHEMBL833161 0.80 GRM4 (0.44) KMT2AMAPTRAB9ANPC1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1572728-B1 POLYMER CONJUGATES WITH DECREASED ANTIGENICITY, METHODS OF PREPARATION AND USES THEREOF MOUNTAIN VIEW PHARMACEUTICALS (US) 2014-06-25 EP claimed
CN-101503351-B Brominated rare-earth carboxylate, as well as preparation and use thereof HUAIHAI INST TECHNOLOGY 2012-08-15 CN claimed
US-20120114742-A1 Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) 2012-05-10 US claimed
US-8129330-B2 Complex of polyoxyethylene glycol with active material MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) 2012-03-06 US claimed
CN-101503351-A Brominated rare-earth carboxylate, as well as preparation and use thereof HUAIHAI INST TECHNOLOGY (CN) 2009-08-12 CN claimed
JP-2006510601-A 2006-03-30 JP claimed
EP-1572728-A2 POLYMER CONJUGATES WITH DECREASED ANTIGENICITY, METHODS OF PREPARATION AND USES THEREOF Mountain View Pharmaceuticals, Inc. (US) 2005-09-14 EP claimed
EP-1421175-A4 POLYMER STABILIZED PROTEINASES MOUNTAIN VIEW PHARMACEUTICALS (US) 2004-12-08 EP claimed
EP-1421175-A2 POLYMER STABILIZED PROTEINASES Mountain View Pharmaceuticals, Inc. (US) 2004-05-26 EP claimed
WO-2004030617-A2 POLYMER CONJUGATES WITH DECREASED ANTIGENICITY, METHODS OF PREPARATION AND USES THEREOF MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) 2004-04-15 WO claimed
US-20040062748-A1 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof MOUNTAIN VIEW PHARMACEUTICALS, INC. 2004-04-01 US claimed
US-20040062746-A1 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof MOUNTAIN VIEW PHARMACEUTICALS, INC. 2004-04-01 US claimed
US-20030012777-A1 Polymer conjugates of proteinases MOUNTAIN VIEW PHARMACEUTICALS, INC. 2003-01-16 US claimed
WO-2003002716-A2 POLYMER STABILIZED PROTEINASES MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) 2003-01-09 WO claimed
CN-122095024-A Flame-retardant aromatic polycarbonate resin composition and molded article thereof 2026-05-26 CN disclosed
EP-4406536-A2 CYSTATHIONINE BETA-SYNTHASE ENZYME FOR TREATMENT OF HOMOCYSTINURIA The Regents of The University of Colorado, A Body Corporate (US) 2024-07-31 EP disclosed
EP-3712264-B1 CYSTATHIONINE BETA-SYNTHASE ENZYME FOR TREATMENT OF HOMOCYSTINURIA UNIV COLORADO REGENTS (US) 2024-04-10 EP disclosed
EP-0402674-A2 Process for preparing Polycarbonate-silicon block copolymer compositions GENERAL ELECTRIC COMPANY (US) 1990-12-19 EP disclosed
EP-0382800-A1 IMPACT MODIFIED POLYAMIDE/AROMATIC POLYCARBONATE BLENDS GENERAL ELECTRIC COMPANY (US) 1990-08-22 EP disclosed
WO-1990002156-A1 IMPACT MODIFIED POLYAMIDE/AROMATIC POLYCARBONATE BLENDS GENERAL ELECTRIC COMPANY (US) 1990-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040062748-A1 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof CD14, HLA-C, HLA-A KMT2A 2567/4885MAPT 1859/4885RAB9A 3103/4885
US-20040062746-A1 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof CD14, HLA-C, HLA-A KMT2A 2567/4885MAPT 1859/4885RAB9A 3103/4885
US-20120114742-A1 Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof CD14, HLA-C, HLA-A KMT2A 2567/4885MAPT 1859/4885RAB9A 3103/4885
US-20030012777-A1 Polymer conjugates of proteinases PRNP, PRSS3, PRSS1 KMT2A 2115/4885MAPT 93/4885RAB9A 1924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.